Figure 1. Analytic Framework

**HCC Screening**
- Ultrasound
- CT
- AFP

**Patients with chronic liver disease**

**Treatment** of screen-detected HCC:
- Resection
- Transplant
- Radiofrequency ablation
- Transarterial chemoembolization
- Sorafenib

**KQ1. Health outcomes:**
- HCC specific mortality
- Liver disease mortality
- All-cause mortality

**KQ2. Adverse effects of screening:**
- Anxiety
- Stress
- Depression
- Liver biopsy related complications
- Renal insufficiency
- Overdiagnosis
- Cost
Figure 2. Median survival in cohort studies of HCC patients diagnosed through screening programs compared with no screening

* * P < 0.05
† P-value was not reported.
‡ Screening group includes patients screened at both 0-6 and 7-24 month intervals before HCC diagnosis.
§ Sixty-one percent of screening group received semi-annual surveillance; 17% received annual surveillance.